Abstract
Introduction
Nowadays kidney morbidity has become common among HIV-infected patients in industrialized countries [1] . Specific renal damages characterise the HIV-associated nephropathy (HIVAN) [2] [3] and several risk factors have been hypothesised and investigated individually including black ethnicity, male gender, history of injection drug use, hepatitis C virus (HCV) co-infection, low CD4+ cell count, and concurrent AIDS-defining condition. HIVAN may result in renal function impairment [4] [5] , although the use of antiretroviral therapy (ART) has recently contributed to lower its prevalence [6] [7] . Nevertheless the overall survival improvement of HIV-infected patients receiving ART leads to the accumulation of factors that are harmful for renal function: ageing, comorbidities such as high blood pressure, diabetes, hyperlipidemia and adverse effects of antiretroviral drugs such as indinavir and tenofovir [8] . These factors are thus likely to increase again the frequency of acute or chronic renal impairment (RI) [9] .
Studies on the frequency of RI in HIV-infected patients have often been conducted in selected groups of HIV-infected patients and additional studies are needed to allow a proper estimation of its prevalence and comprehensive investigation of its determinants [10] .
The objectives of our study were to estimate the prevalence of RI in a large and unselected cohort of HIV-infected patients in care and to identify associated factors that could lead to specific preventive or control measures.
Patients and Methods
We performed a cross-sectional survey within the French Agency of AIDS and Hepatitis Research (ANRS) CO3 Aquitaine Cohort of HIV-infected patients living and followed in South-western France. Patients were enrolled prospectively in this cohort through a hospital-based surveillance system, if they were aged 13 years or more and provided informed consent. Standardized epidemiological, clinical, biological and therapeutic data collection was completed by attending physicians at time of enrollment and at each hospital follow-up visit, generally every three or six months (in agreement with French recommendations for standards of care) or more frequently in case of intercurrent event, then verified and coded by research nurses with annual audit for quality control.
The main outcome of interest in our study was the renal filtration rate assessed by a single measurement of the clearance of creatinine (CC) using Cockcroft-Gault formula [11] owing to the fact that creatininemia was routinely registered in our data base from January 2004. Créatinine was measured by Jaffé methodology in the three laboratories where measurements have been carried out and calibrations have been performed to assure comparability. We did not standardize CG measurement for body surface area as there is no general consensus of whether or not this has to be performed [9] . The lack of data related to ethnicity in our systematic survey did not allow the use of the Modification of Diet in Renal Disease (MDRD) formula to assess the renal function; nevertheless crude prevalence of RI was calculated using modified MDRD formula [12] , which does not need to know ethnicity, to allow comparisons with other studies: CC ml/mn = 175 x (serum creatinine µM/l x 0.0113) -1,154 x age -0,203 x 0.742 (if female).
We included in the analysis data of the cohort participants at the time of first follow-up where a Statistical analysis. Prevalence of RI was computed as the number of cases of RI per 100 patients followed in the period. We calculated the crude overall RI prevalence and specific rate for each stage of RI. Patients' characteristics were selected for inclusion in the multivariate model of determinants of RI if they were significantly associated in the univariate analysis (p<0.25). We compared patients according to the two following thresholds: 90 ml/min (any RI) and 60 ml/min (advanced RI). In order to correct for the weaknesses due to response variable dichotomization [13] , we performed a polynomial logistic regression which allowed to compare two by two, the categories of patients with normal renal function, those with mild RI and those with advanced RI.
Models were fitted using the SAS software (version 9.1.3, SAS Institute Inc., Cary, NC, USA).
Interaction terms combining primary exposure and confounding measures were evaluated. A backward elimination procedure was used to determine the most parsimonious model. All statistical tests were two-sided and a p-value of 0.05 was considered as significant. A first multivariate logistic regression model (threshold of RF: 90 ml/min) showed that the overall RI (CC<90 ml/min) prevalence was significantly greater in female and older patients, those with a low BMI, an HIV transmission group other than drug abuse, undetectable VL, and tenofovir exposure (Table 1) .
Results

Population characteristics
When RI was estimated with simplified MDRD-based calculations, undetectable viral load was no In another multivariate model advanced RI (CC<60 ml/min) was only associated with female gender, older age, low BMI, high blood pressure and indinavir exposure >1 year (Table 2) . Finally the polynomial regression model (Table 3) showed a significant association of mild RI (60<CC<90 ml/min), as compared with normal renal function, with female gender, older age, low BMI, HIV transmission group other than intravenous drug use, tenofovir exposure. For advanced RI (as compared with mild RI), the associated factors were older age, low BMI, high blood pressure and indinavir exposure.
It should be noted that mean exposure durations to antiretroviral-associated RI, i.e. tenofovir and indinavir, were significantly longer among patients with RI compared to those without RI : 4.7 months versus 3.3 months for tenofovir and 8.5 versus 6.1 months for indinavir (p< 10 -3 for both comparisons).
Discussion
Our study examined the prevalence of RI and its associated factors among HIV-infected persons under care in South-Western France in the most recent era of use of ART.
Our data revealed a high prevalence of RI (CC <90 ml/min) as measured by CG equation formula (39%) in this HIV-infected population. Although a lower overall prevalence of RI (28%) was recently reported in such patients followed in the US Navy [14] , these frequencies are much higher than the prevalence observed in the general population of the same age, i.e. 7.7% in a representative sample of 15 625 US non-institutionalized adults aged 20 years or older [15] .
The prevalence of advanced stage of RI (CC <60 ml/min) in our study (4.9% -using CG formula) is close to that reported in the EuroSIDA cohort (3.5% using CG and 4.7% using Modification of Diet in Renal Disease (MDRD) formula) [9] , 5.9% in the MACS cohort [16] and 5.7 % in the King's College Hospital Cohort ( [17] .This figure was slightly higher in the Washington University HIV outpatient clinic (7.3%) [18] , in the Johns Hopkins HIV cohort (7%) [19] and in a cross sectional survey in Barcelona (7.6%) [20] .
The epidemiological differences between the studied populations can explain some of the differences between these results; indeed the traditional risk factors of renal insufficiency (high blood pressure, diabetes, dyslipidemia, age, ethnicity) and those specific to HIV disease are differentially distributed in the various studies. The different definitions of RI used in the studies (i.e.; acute versus chronic RI where confirmed value is required, additional adjustment of formulae for body surface area) could also contribute to the differences noticed between the studies.
Conversely to the overall prevalence of RI, the prevalence of advanced RI is close to what has been reported in the general population: 4.7% in the US population [15] , 5.7% in a Galician population whose average age was 49.5 years [21] , 5.6 % in the control group of study conducted in Catalona [20] .
In our study, patients with RI were more likely to be female, older, to have a low BMI, high blood pressure or an exposure to tenofovir or indinavir >1 year.
The gender, age and BMI reflect the physiological changes of the glomerular filtration rate which are moreover taken into account in the CG formula. These factors are thus logically identified in our study as in most of the available literature [9, 10, 14, 18, 19, 22] . In one report [20] , the presence of lipoatrophy was also independently associated with advanced RI; we did not study this factor but this finding is compatible with the association of a low BMI with RI.
High blood pressure, which is a well known risk factor for renal function impairment in the general population, was associated with advanced RI within our HIV-infected population, as in previous but not all reports [9, 14, 18] . The increased risk observed among patients with high blood pressure justifies sensitizing physicians to the screening and treatment of hypertension to reduce the likelihood of developing RI.
Conversely to some previous studies [9, 14, 17, 22] we did not identify any association between advanced HIV infection (AIDS stage, low CD4 count) and RI. This does not exclude the hypothesis that advanced HIV disease could be associated (through HIVAN) with severe (CC<30ml/mn) and/or end-stage (CC<15ml/mn) renal insufficiency but this has not be tested as too few patients were diagnosed at these RF stages (n=13). The absence of association with HIV-related factors in our study can also be due to the fact that most of these reports dealt specifically with acute RI which represents a minor part of the cases of RI impairment observed in our study; so in the King's college report more than half of all acute RI s occurred within three months after initiation of HIV care typically in patients with opportunistic infections or HIV-associated malignancies [17] .
Despite evidence for a direct renal pathogenic role of HIV [2, 3] only one study has observed an association between high VL and RI [23] , an observation we did not replicate. The association of undetectable viral load with RI, found in only one of the multivariate models, is contra intuitive and reflects very likely the potential deleterious effect of some antiretroviral drugs as further discussed.
We did not demonstrate the beneficial effect on renal function (mainly by decreasing HIVAN) of antiretroviral therapy overall, as it has been suggested in other studies [6] [7] , although the observation of the ORs describing the association of RI and exposure to some antiretroviral drugs is in favour of a protective (OR < 1) renal impact of NNRTIs and PIs other than indinavir (tables 1 and 2). Conversely, we identified an association of the cumulative use, even short (i.e. a few months), of other antiretroviral drugs (indinavir and tenofovir) with renal function impairment. In accordance with other reports [9, 14, [24] [25] [26] [27] [28] , our results indicate an association of mild RI with the use of tenofovir. In an additional analysis where current use of tenofovir was added to the model, we found a statistical association between this latter variable but no more with cumulative exposure to the drug. Our results could thus support the hypothesis that tenofovir use may result in functional renal tubular deficits, which could normalize after withdrawal of the drug, but not necessarily in structural defects [29] . A recent report showed a mild but significant difference between change from baseline of the glomerular filtration rate (CG formula) in patients treated three years with tenofovir as compared to those receiving control drug (-2 ml/mn vs + 5 ml/mn) [30] . This study population was nevertheless quite different from an unselected cohort as data came from clinical trials including patients whose median age was younger (36 years), and with few baseline renal abnormalities and risk factors such as hypertension, diabetes and hyperlipidemia. Our data showing an association of tenofovir use and mild (but not advanced) RI in routine practice are not contradictory with these clinical trial results. .We can nevertheless conclude that some factors favouring renal function impairment have to be taken into account before starting tenofovir use either to consider alternative antiretroviral drug or to lead to a closer monitoring of renal function:
prexisting RI, recent or concomitant use of nephrotoxic drugs or didanosine (which increases tenofovir plasma concentration), diabetes mellitus, high blood pressure [9, 17, 29, 30, 31] . One study showed also the deleterious effect of the co-prescription of boosted PIs [32] .
In our study indinavir was associated with advanced RI. This finding has been reported by other authors and is in accordance with the leading mechanism of nephrotoxicity of this drug [14, [33] [34] [35] .
Nevertheless the decreasing use of this drug in current practice limits the deleterious public health impact of this molecule at least in industrialized countries.
We did not find as others any association of HCV co-infection with RI. This is probably due to the fact that, in previous reports, HCV co-infection was associated either with late-onset acute RI [17] or observed in patients with advanced chronic hepatitis or cirrhosis [31] .
The susceptibility to RI of black patients, considered as especially susceptible to HIVAN, could not be evaluated as ethnicity is not registered in our data-base. We can nevertheless attest that patients enrolled in the Aquitaine cohort are very mostly of white ethnic origin.
Some limitations of our study should be noted as causal relationships, including association between RI and exposure to antiretroviral drugs, cannot be formally established from a crosssectional survey design. We advertise for carefully designed and conducted prospective follow-up studies to undoubtedly identify the factors associated with the occurrence of RI; such cohorts should also allow distinguishing acute from chronic RI [9, 19] .
Another possible limitation of the current study is the use of the CG formula to assess the renal function. This assessment is indeed an estimation and can lead to misclassification of some patients.
Hence, CG and MDRD are both admitted formulas for renal function estimation [12, [36] [37] [38] . There is no general consensus in HIV-infected patients as to the most appropriate formula to use for estimating the glomerular filtration rate (GFR) although the CG formula may be more appropriate in younger and thin subjects, that is mainly the case in HIV-infected patients [39] . In our study comparisons of data using CG formula and modified MDRD-based calculations are in favour of a slight underestimation of prevalence of RI, mainly mild, when estimated with CG formula.
Recently in an HIV-infected population the CG formula was found at least equal to the MDRD one with regard to GFR-measurement with [ 125 I]-iothalamate, considered as the gold standard [40] .
In conclusion, results from the current study indicate the importance of the investigation of renal function among HIV-infected patients in care, especially in women, older patients, those with low BMI, and/or treated by tenofovir or indinavir.
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